
Zymeworks Inc (ZYME) Stock Forecast & Price Target
Zymeworks Inc (ZYME) Analyst Ratings
Bulls say
Zymeworks Inc. has demonstrated significant clinical advancements with its clinical candidate, zanidatamab, showing highly statistically significant improvements in progression-free survival and overall survival in combination therapies, which positions it favorably against traditional therapies. The company is transitioning to a royalty-driven business model, with projected peak risk-adjusted sales of $1.5 billion for Ziihera, bolstered by attractive mid-single-digit royalty streams from partnerships, contributing to its robust financial outlook. With a cash position of $299 million and an additional $440 million in potential near-term milestones, Zymeworks is well-equipped to sustain its innovative R&D while capitalizing on its commercial opportunities.
Bears say
Zymeworks Inc faces significant challenges that contribute to a negative outlook on its stock. Key risks include the potential failure of core assets like zanidatamab in clinical trials, which could halt development and exert downward pressure on the stock. Additionally, the company may struggle with capital constraints and dilution risks if it fails to secure financing under favorable market conditions, potentially leading to insolvency.
This aggregate rating is based on analysts' research of Zymeworks Inc and is not a guaranteed prediction by Public.com or investment advice.
Zymeworks Inc (ZYME) Analyst Forecast & Price Prediction
Start investing in Zymeworks Inc (ZYME)
Order type
Buy in
Order amount
Est. shares
0 shares